PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

NCT07277842 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

382

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Low Rectal Adenocarcinoma
pMMR (Microsatellite Stable Rectal Cancer)

Interventions

DRUG: Serplulimab
DRUG: FOLFOXIRI chemotherapy
DRUG: CAPOX chemotherapy
RADIATION: Long-course pelvic radiotherapy

Sponsor

Sun Yat-sen University